Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonalcoholic Fatty liver disease.

Roberta A Jorgensen1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 44905, USA. Jorgensen.Roberta@mayo.edu

Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates
|August 16, 2003
PubMed
Summary

Nonalcoholic fatty liver disease (NAFLD) is a growing cause of cirrhosis, often linked to obesity and diabetes. Gradual weight reduction shows promise for improving liver health in affected individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis.

American journal of therapeutics·2016
Same author

Serum lipids in primary sclerosing cholangitis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2011
Same author

Varices in early histological stage primary biliary cirrhosis.

Journal of clinical gastroenterology·2010
Same author

Fatigue in primary biliary cirrhosis.

Nature reviews. Gastroenterology & hepatology·2010
Same author

Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Digestive diseases and sciences·2009
Same author

Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study.

The American journal of gastroenterology·2008

Area of Science:

  • Hepatology
  • Internal Medicine
  • Metabolic Diseases

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a significant cause of cirrhosis and end-stage liver disease.
  • Histologically similar to alcoholic liver disease, NAFLD affects individuals with minimal alcohol consumption.
  • The NAFLD spectrum ranges from simple steatosis to inflammation, fibrosis, and cirrhosis.

Purpose of the Study:

  • To review the current understanding of nonalcoholic fatty liver disease.
  • To highlight associated conditions and potential etiological factors.
  • To discuss clinical presentation, prognosis, and management strategies.

Main Methods:

  • Review of existing literature on nonalcoholic fatty liver disease.
  • Analysis of epidemiological data and clinical observations.

Related Experiment Videos

  • Synthesis of information on pathophysiology and treatment outcomes.

    • Main Results:

    • NAFLD is frequently associated with obesity, Type 2 diabetes, and hyperlipidemia.
    • Insulin resistance is considered a key factor in NAFLD development.
    • Patients often present with elevated aminotransferases; symptoms may include fatigue and abdominal pain.
    • The natural history is poorly understood, but progression to end-stage liver disease and transplantation can occur.

    Conclusions:

    • No universally effective medical treatment for NAFLD currently exists.
    • Gradual weight reduction is recommended for overweight or obese patients and has shown improvement in liver test abnormalities.
    • Further research into the natural history and effective treatments for NAFLD is warranted.